Ovid Therapeutics Inc Cash Flow Conversion Efficiency
Ovid Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Ovid Therapeutics Inc (OVID) has a cash flow conversion efficiency ratio of -0.084x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.59 Million) by net assets ($209.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ovid Therapeutics Inc (2014–2025)
Cash flow conversion efficiency of Ovid Therapeutics Inc from 2014 to 2025. This chart illustrates how Ovid Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ovid Therapeutics Inc (OVID) stock price for real-time trading data and today's change.
Ovid Therapeutics Inc Cash Flow Conversion Ratio Explained
Ovid Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ovid Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ovid Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Ovid Therapeutics Inc (OVID) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qinghai Huzhu Barley Wine Co Ltd
SHE:002646
|
0.000x |
|
Jinxiandai Information Industry Co
SHE:300830
|
0.012x |
|
Zhejiang Tiancheng Control Co
SHG:603085
|
0.100x |
|
HeNan Splendor Science & Technology Co Ltd
SHE:002296
|
0.019x |
|
Xinhua Winshare Publishing and Media Co. Ltd
F:SXV
|
0.026x |
|
Golden Eagle Energy Tbk
JK:SMMT
|
-0.120x |
|
Beijing Trust Far Tech
SHE:300231
|
0.094x |
|
Anpec Electronics
TWO:6138
|
0.041x |
Annual Cash Flow Conversion Efficiency for Ovid Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Ovid Therapeutics Inc from 2014 to 2025. Review Ovid Therapeutics Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.66 Million | $-38.33 Million | -0.293x | +64.23% |
| 2024-12-31 | $68.23 Million | $-55.96 Million | -0.820x | -57.29% |
| 2023-12-31 | $87.80 Million | $-45.78 Million | -0.521x | -24.89% |
| 2022-12-31 | $132.27 Million | $-55.23 Million | -0.418x | -163.27% |
| 2021-12-31 | $179.75 Million | $118.61 Million | 0.660x | +155.82% |
| 2020-12-31 | $43.63 Million | $-51.58 Million | -1.182x | -62.04% |
| 2019-12-31 | $70.02 Million | $-51.09 Million | -0.730x | +37.85% |
| 2018-12-31 | $38.81 Million | $-45.56 Million | -1.174x | -211.27% |
| 2017-12-31 | $83.44 Million | $-31.47 Million | -0.377x | -4.44% |
| 2016-12-31 | $49.29 Million | $-17.80 Million | -0.361x | -348.12% |
| 2015-12-31 | $68.07 Million | $-5.49 Million | -0.081x | -46.14% |
| 2014-12-31 | $4.74 Million | $-261.28K | -0.055x | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human or… Read more